News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Jun 19, 2007
GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its interim results for the six months ended 31 March 2007.
Jun 04, 2007
GW Commences Phase I Study of THCV, a Potential Treatment for Obesity and Related Metabolic Disorders
Mar 22, 2007
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co.
Mar 15, 2007
GW Pharmaceuticals plc (AIM: GWP) today announces the appointment of Mr Richard Forrest as a non-executive director.
Feb 28, 2007
GW Pharmaceuticals plc (AIM: GWP) a leading neurology journal, The European Journal of Neurology, today reports a study showing that Sativex significantly reduces intractable spasticity (spasms and stiffness) in peo
Feb 14, 2007
GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co., Ltd. today announce that they have entered into a major long term strategic cannabinoid alliance.
Jan 30, 2007
Porton Down, UK, 30 January 2007: GW Pharmaceuticals plc (AIM: GWP), the developer and manufacturer of a range of new cannabinoid medicines, including Sativex®, announces its preliminary results for
Jan 26, 2007
Porton Down, UK, 26 January 2007: GW Pharmaceuticals plc (AIM: GWP) is pleased to announce the appointment of James Noble as an independent non-executive director with immediate effect.
Jan 15, 2007
GW Pharmaceuticals plc (“GW”) today announces preliminary results of two Phase III studies of Sativex®, its cannabinoid spray medicine, in peripheral neuropathic pain.

Pages